Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports.
- 1Department of Urology Japanese Red Cross Akita Hospital Akita City Japan.
- 2Department of Urology Akita University Graduate School of Medicine Akita City Japan.
Abstract
Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis. Case 1 was a 77-year-old man with lung metastasis who received cabozantinib after multiple systemic therapies. Cabozantinib was started at 20 mg/day before hemodialysis; hemodialysis began 8 months later, and treatment continued for 59 months with tolerability-guided schedule modification. Case 2 was a 69-year-old man on maintenance hemodialysis who received cabozantinib 20 mg/day for lung and bone metastases. The schedule was changed to alternate-day dosing. Partial response was achieved, but treatment was discontinued after 4 months because of worsening general condition. Cabozantinib was administered with individualized dose adjustment and careful monitoring; further clinical and pharmacokinetic data are needed to establish optimal dosing.
Related
- Exceptionally Durable Response to First-Line S-1 Monotherapy in Metastatic Pancreatic Adenocarcinoma: A Case Report
- Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
- CABOPRE: Evaluating Perioperative Cabozantinib’s Efficacy and Biomarkers for Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma
- Construction of a five-gene prognostic model involving T cell exhaustion and metabolic reprogramming for predicting hepatocellular carcinoma risk using LASSO: insights into immune infiltration and drug sensitivity
- Metachronous Metastatic Invasive Breast Carcinoma and Metastatic Small Cell Carcinoma Clinically and Radiologically Favoured to Be of Pulmonary Origin: A Case Report
BibTeX
@article{nara2026cabozantinib,
title = {{Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports.}},
author = {Taketoshi Nara and Kengo Furihata and Kazuma Sato and Takuma Sato and Naoko Honma and Yohei Horikawa and Naotake Shimoda},
journal = {IJU case reports},
year = {2026},
month = nov,
doi = {10.1002/iju5.70291},
url = {https://europepmc.org/article/MED/42997484},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports.
AU - Taketoshi Nara
AU - Kengo Furihata
AU - Kazuma Sato
AU - Takuma Sato
AU - Naoko Honma
AU - Yohei Horikawa
AU - Naotake Shimoda
PY - 2026
DA - 2026/11/06
JO - IJU case reports
DO - 10.1002/iju5.70291
UR - https://europepmc.org/article/MED/42997484
AB - Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis. Case 1 was a 77-year-old man with lung metastasis who received cabozantinib after multiple systemic therapies. Cabozantinib was started at 20 mg/day before hemodialysis; hemodialysis began 8 months later, and treatment continued for 59 months with tolerability-guided schedule modification. Case 2 was a 69-year-old man on maintenance hemodialysis who received cabozantinib 20 mg/day for lung and bone metastases. The schedule was changed to alternate-day dosing. Partial response was achieved, but treatment was discontinued after 4 months because of worsening general condition. Cabozantinib was administered with individualized dose adjustment and careful monitoring; further clinical and pharmacokinetic data are needed to establish optimal dosing.
SN - 2577-171X
ER -